CAS: 1282549-08-9

Potent antagonist of type 1 receptor lysophosphatidic acid (LPA1), selective over other LPA subtypes at least by ten-fold. Blocks LPA-induced contraction in urethra and prostate, as well as proliferation of prostatic stromal cells. These findings indicate a potential use of ASP 6432 for the treatment of lower urinary tract symptoms and benign prostatic hyperplasia (LUTS/BPH).

ASP6432 is an antagonist of type 1 lysophosphatidic acid receptor (LPA1). For human LPA1 and rat LPA1, the IC50s are 11 nM and 30 nM , respectively.